Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas

Lung Cancer

Volumn 45, Issue 2, 2004, Pages 161-169

  Araki, Kunio ^a   Hashimoto, Kiyoshi ^a   Ardyanto, Tonang Dwi ^a   Osaki, Mitsuhiko ^a   Shomori, Kohei ^a   Nakamura, Hiroshige ^b   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b National Yonago Hospital   (Japan)

Author keywords

Bronchial adenocarcinoma (AC); Cyclooxygenase (Cox) 2; Epidermal growth factor receptor (EGFR); Immunohistochemistry; Ki 67; P53; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG SURGERY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, NEEDLE; BRONCHIAL NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 3042759273     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.01.013     Document Type: Article

References (45)

1. World Health Organization. Histological typing of lung and pleural tumors. In: International histological classification of tumors, 3rd ed. Geneva: World Health Organization; 1999.
2. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiovasc. Surg. 96:1998;440-447
3. Suzuki K., Nagai K., Yoshida J., Nishimura M., Takahashi K., Yokose T., et al. Conventional clinicopathologic prognostic factors in surgically resected non-small cell lung carcinoma. Cancer. 86:1999;1976-1983
4. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol. 15:1997;2858-2865
5. Neal G., Anju M., Gary C., Robert W., Stewart P. Prognostic factors in T1N0M0 adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am. J. Clin. Pathol. 112:1999;391-402
6. Koga T., Hashimoto S., Sugio K., Yoshino I., Sepideh M., Matsuo Y., et al. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin. Cancer Res. 7:2001;1730-1738
7. Ito H., Oshima F., Kameda Y., Suzuki R., Ikehara M., Arai H., et al. Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol. Rep. 9:2002;119-123
8. Saijo Y., Sato G., Usui K., Sato M., Sagawa M., Kondo T., et al. Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma. Ann. Oncol. 12:2001;1121-1125
9. Hayashi H., Ogawa N., Ishiwa N., Yazawa T., Inayama Y., Ito T., et al. High cyclin E and low p27/Kip 1 expression are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer. 34:2001;59-65
10. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). Natl. Cancer Inst. (Bethesda). 90:1998;1529-1536
11. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. (Bethesda). 90:1998;1609-1620
12. Sano H., Kuwahito Y., Wilder R., Hashiramoto A., Mukai S., Asahi K., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789
13. Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1997;1276-1280
14. Kase S., Osaki M., Honjo S., Adachi H., Kaibara N., Ito H., et al. Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch. 442:2003;129-135
15. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 90:1998;455-460
16. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinoma. Cancer Res. 58:1998;3761-3764
17. Wolff H., Saukkonen K., Annttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001
18. Kim Y.B., Kim G.E., Cho N.H., Pyo H.R., Shim S.J., Chang S.K., et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer. 95:2002;531-539
19. Gallo O., Masini E., Bianchi B., Bruschini L., Paglierani M., Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum. Pathol. 33:2002;708-714
20. Edwards J.G., Faux S.P., Plummer S.M., Abrams K.R., Walker R.A., Waller D.A., et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin. Cancer Res. 8:2002;1857-1862
21. Ari R., Anna S., Johan L., Mikael L., Tiina S., Caj H., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62:2002;632-635
22. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7:2001;861-867
23. Achiwa H., Yatabe Y., Hida T., Kuroishi T., Kozaki K., Nakamura S., et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res. 5:1999;1001-1005
24. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8:2002;289-293
25. Niki T., Kohno T., Iba S., Moriya Y., Takahashi Y., Saito M., et al. Frequent co-localization of Cox-2 and laminin-5γ2 chain at the invasive front of early-stage lung adenocarcinomas. Am. J. Pathol. 160:2002;1129-1141
26. Rice P.L., Washington M., Schleman S., Beard K.S., Driggers L.J., Ahnen D.J. Sulindac Sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 63:2003;616-620
27. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., et al. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6:2000;1024-1028
28. Sobin LH, Wittekind Ch., editors. International Union Against Cancer: TNM Classification of Malignant Tumours, 5th ed. New York: John Wiley & Sons; 1997. p. 91-100.
29. Hasturk S., Kemp B., Kalapurakal S.K., Kurie J.M., Hong W.K., Lee J.S. Expression of cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer. 94:2002;1023-1031
30. Selvaggi G., Novello S., Torri V., Leonardo E., De Giuli P., Borasio P., et al. Epidermal growth factor receptor expression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann. Oncol. 15:2004;28-32
31. Ohike N., Morohashi T. Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation. Patolo Int. 51:2001;770-777
32. Yang Q., Yoshimura G., Suzuma T., Tamaki T., Umemura T., Nakamura M., et al. clinicopatological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin. Cancer Res. 7:2001;3869-3873
33. Thun M.J., Mohan M., Namboodiri B.S., Heath G.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 3258:1991;1593-1596
34. Giardielo F.J., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Gelano P., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1993;1313-1316
35. Kawamori T., Rao C.V., Seibert K., Reddy B.D. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412
36. Sheng H., Shao J., Kirkland S.C., Isakson P., Coffey R.J., Morrow J., et al. Inhibition of human colon cell cancer growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99:1997;2254-2259
37. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6:2000;2006-2011
38. Hida T., Kozaki K., Ito H., Miyaishi O., Tatematsu Y., Suzuki T., et al. Significant growth inhibition of human lung cancer cell lines both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin. Cancer Res. 8:2002;2443-2447
39. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 58:1998;5354-5360
40. Saccomanno G., Archer V.E., Auerbach O., Saunders R.P., Brennan L.M. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer. 33:1974;256-270
41. Leung W.K., To K.F., Ng Y.P., Lee T.L., Lau J.Y., Chan F.K., et al. Association between cyclo-oxygenase-2 overexpression and missence p53 mutations in gastric cancer. Br. J. Cancer. 84:2001;335-339
42. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274:1999;10911-10915
43. Lonardo F., Dragnev K.H., Freemantle S.J., Ma Y., Memoli N., Sekula D., et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin. Cancer Res. 8:2002;54-60
44. Sah J.F., Eckert R.L., Chandraratna R.A., Rorke E.A. Retinoids suppress epidermal growth factor receptor-dependent ERK1/2 activation. J. Biol. Chem. 277:2002;9728-9735
45. Carter C.A., Shaw B.L. Retinoic acid affects the EGF-R signaling pathway during differentiation induction of human endometrial adenocarcinoma cells. Exp. Mol. Pathol. 68:2000;170-186